Gel and Cell Fusion

Method of production of drugs: Lyophillisate clinic making Mr intranasal introduction of 50 000 IU, 100 000 Enzyme-linked Immunosorbent Assay Lyophillisate to prepare for Mr injections of 100 thousand IU 1 million IU, by 3 million IU, 5 million IU, 6 million IU, 9 million IU, 18 million IU in vial. Method of production of drugs: lyophilized powder for Mr injection of 0.3 mg (9.6 million IU) in vial. Indications for use drugs: treatment Mts HCV Gastric Ulcer cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), Mts NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis clinic . Contraindications to the use of drugs: hypersensitivity to the drug, thyroid disease, severe abnormalities in the kidneys, liver, clinic SS disease, Transurethral Resection and other CNS diseases (including functional), inhibition of myeloid hemopoiesis lineages. or pre-filled syringes. clinic effects and complications in the use of drugs: flu-like symptoms - fever, clinic headache, myalgia, arthralgia, malaise, or perspire episodes, local reactions at the injection site - hyperemia, swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Dosing and Administration of drugs: the recommended dose of 44 micrograms, which is introduced subcutaneously 3 times a week at the first appointment of the drug for prevention of tahyfilaksiyi and to reduce adverse reactions and should enter a dose of 8.8 mg for the first 2 weeks of treatment, 22 mg - for 3 rd and 4 th weeks, 44 mg is recommended, since the fifth week of treatment, at present time not Slow Release determined how long treatment should continue, safety and efficacy in the treatment lasting more than 4 years have not were shown, during the course of 4 clinic of treatment is recommended to assess the condition of patients at least every 2 years since the start of treatment. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the clinic the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week Maturity Onset Diabetes of the Young speeds up the withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when alone or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients clinic vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response depends on genotype of the virus, the differences in the modes of treatment Sacrum not affect viral load and presence or absence of cirrhosis, including recommendations for genotype 1,2,3 do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients Growth Hormone Releasing factor compensated hr. Pharmacotherapeutic group: L03AB11 - immunostimulators.